The metabolism of drug2 can be increased when combined with drug1.
 8809 
The metabolism of drug1 can be increased when combined with drug2.
 8809 
The risk or severity of adverse effects can be increased when drug2 is combined with drug1.
 8278 
The risk or severity of adverse effects can be increased when drug1 is combined with drug2.
 8278 
drug1 may decrease the excretion rate of drug2 which could result in a higher serum level.
 4863 
drug2 may decrease the excretion rate of drug1 which could result in a higher serum level.
 4863 
The therapeutic efficacy of drug1 can be decreased when used in combination with drug2.
 3969 
The therapeutic efficacy of drug2 can be decreased when used in combination with drug1.
 3969 
The risk or severity of hypoglycemia can be increased when drug2 is combined with drug1.
 2292 
The risk or severity of hypoglycemia can be increased when drug1 is combined with drug2.
 2292 
The serum concentration of drug1 can be increased when it is combined with drug2.
 2073 
The serum concentration of drug2 can be increased when it is combined with drug1.
 2073 
The risk or severity of bleeding can be increased when drug2 is combined with drug1.
 2008 
The risk or severity of bleeding can be increased when drug1 is combined with drug2.
 2008 
The metabolism of drug2 can be decreased when combined with drug1.
 1602 
The metabolism of drug1 can be decreased when combined with drug2.
 1602 
The risk or severity of methemoglobinemia can be increased when drug1 is combined with drug2.
 1238 
The risk or severity of methemoglobinemia can be increased when drug2 is combined with drug1.
 1238 
drug2 may increase the thrombogenic activities of drug1.
 1162 
drug1 may increase the thrombogenic activities of drug2.
 1162 
The therapeutic efficacy of drug1 can be increased when used in combination with drug2.
 982 
The therapeutic efficacy of drug2 can be increased when used in combination with drug1.
 982 
The risk or severity of hyperglycemia can be increased when drug2 is combined with drug1.
 924 
The risk or severity of hyperglycemia can be increased when drug1 is combined with drug2.
 924 
The risk or severity of bleeding and hemorrhage can be increased when drug2 is combined with drug1.
 755 
The risk or severity of bleeding and hemorrhage can be increased when drug1 is combined with drug2.
 755 
The risk or severity of QTc prolongation can be increased when drug1 is combined with drug2.
 566 
The risk or severity of QTc prolongation can be increased when drug2 is combined with drug1.
 566 
The risk or severity of CNS depression can be increased when drug1 is combined with drug2.
 529 
The risk or severity of CNS depression can be increased when drug2 is combined with drug1.
 529 
drug2 may increase the hypoglycemic activities of drug1.
 465 
drug1 may increase the hypoglycemic activities of drug2.
 465 
The risk or severity of Thrombosis can be increased when drug2 is combined with drug1.
 446 
The risk or severity of Thrombosis can be increased when drug1 is combined with drug2.
 446 
drug1 may increase the excretion rate of drug2 which could result in a lower serum level and potentially a reduction in efficacy.
 371 
drug2 may increase the excretion rate of drug1 which could result in a lower serum level and potentially a reduction in efficacy.
 371 
drug2 may increase the immunosuppressive activities of drug1.
 308 
drug1 may increase the immunosuppressive activities of drug2.
 308 
drug1 may increase the hypotensive activities of drug2.
 296 
drug2 may increase the hypotensive activities of drug1.
 296 
drug1 may decrease the hypoglycemic activities of drug2.
 288 
drug2 may decrease the hypoglycemic activities of drug1.
 288 
The risk or severity of immunosuppression can be increased when drug1 is combined with drug2.
 241 
The risk or severity of immunosuppression can be increased when drug2 is combined with drug1.
 241 
drug2 may increase the anticoagulant activities of drug1.
 236 
drug1 may increase the anticoagulant activities of drug2.
 236 
The risk or severity of neutropenia can be increased when drug1 is combined with drug2.
 197 
The risk or severity of neutropenia can be increased when drug2 is combined with drug1.
 197 
The risk or severity of angioedema can be increased when drug1 is combined with drug2.
 180 
The risk or severity of angioedema can be increased when drug2 is combined with drug1.
 180 
The risk or severity of infection can be increased when drug2 is combined with drug1.
 175 
The risk or severity of infection can be increased when drug1 is combined with drug2.
 175 
The serum concentration of drug2 can be decreased when it is combined with drug1.
 157 
The serum concentration of drug1 can be decreased when it is combined with drug2.
 157 
The risk or severity of neutropenia and thrombocytopenia can be increased when drug2 is combined with drug1.
 136 
The risk or severity of neutropenia and thrombocytopenia can be increased when drug1 is combined with drug2.
 136 
drug1 may increase the bradycardic activities of drug2.
 125 
drug2 may increase the bradycardic activities of drug1.
 125 
The risk or severity of hemorrhage can be increased when drug2 is combined with drug1.
 107 
The risk or severity of hemorrhage can be increased when drug1 is combined with drug2.
 107 
drug2 may decrease the anticoagulant activities of drug1.
 100 
drug1 may decrease the anticoagulant activities of drug2.
 100 
drug1 may increase the myelosuppressive activities of drug2.
 94 
drug2 may increase the myelosuppressive activities of drug1.
 94 
The risk or severity of myelosuppression can be increased when drug2 is combined with drug1.
 92 
The risk or severity of myelosuppression can be increased when drug1 is combined with drug2.
 92 
drug2 may increase the gastrointestinal motility reducing activities of drug1.
 89 
drug1 may increase the gastrointestinal motility reducing activities of drug2.
 89 
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug1 is combined with drug2.
 86 
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when drug2 is combined with drug1.
 86 
The risk or severity of cardiotoxicity can be increased when drug1 is combined with drug2.
 79 
The risk or severity of cardiotoxicity can be increased when drug2 is combined with drug1.
 79 
The risk or severity of bleeding and bruising can be increased when drug1 is combined with drug2.
 72 
The risk or severity of bleeding and bruising can be increased when drug2 is combined with drug1.
 72 
drug2 can cause a decrease in the absorption of drug1 resulting in a reduced serum concentration and potentially a decrease in efficacy.
 58 
The risk or severity of gastrointestinal irritation can be increased when drug2 is combined with drug1.
 58 
drug1 can cause a decrease in the absorption of drug2 resulting in a reduced serum concentration and potentially a decrease in efficacy.
 58 
The risk or severity of gastrointestinal irritation can be increased when drug1 is combined with drug2.
 58 
drug2 may increase the orthostatic hypotensive activities of drug1.
 53 
drug1 may increase the orthostatic hypotensive activities of drug2.
 53 
The risk or severity of myopathy and weakness can be increased when drug1 is combined with drug2.
 52 
The risk or severity of myopathy and weakness can be increased when drug2 is combined with drug1.
 52 
The risk or severity of Cardiac Arrhythmia can be increased when drug1 is combined with drug2.
 44 
The risk or severity of Cardiac Arrhythmia can be increased when drug2 is combined with drug1.
 44 
drug1 may increase the central nervous system depressant (CNS depressant) activities of drug2.
 40 
drug2 may increase the central nervous system depressant (CNS depressant) activities of drug1.
 40 
The serum concentration of the active metabolites of drug2 can be reduced when drug2 is used in combination with drug1 resulting in a loss in efficacy.
 39 
The serum concentration of the active metabolites of drug1 can be reduced when drug1 is used in combination with drug2 resulting in a loss in efficacy.
 39 
The risk or severity of peripheral neuropathy can be increased when drug1 is combined with drug2.
 37 
The risk or severity of peripheral neuropathy can be increased when drug2 is combined with drug1.
 37 
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when drug1 is combined with drug2.
 32 
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when drug2 is combined with drug1.
 32 
drug1 may increase the neuromuscular blocking activities of drug2.
 30 
drug2 may increase the neuromuscular blocking activities of drug1.
 30 
The risk or severity of hypokalemia can be increased when drug2 is combined with drug1.
 29 
The risk or severity of hypokalemia can be increased when drug1 is combined with drug2.
 29 
The risk or severity of hypertension can be increased when drug1 is combined with drug2.
 27 
drug1 can cause an increase in the absorption of drug2 resulting in an increased serum concentration and potentially a worsening of adverse effects.
 27 
The risk or severity of hypertension can be increased when drug2 is combined with drug1.
 27 
drug2 can cause an increase in the absorption of drug1 resulting in an increased serum concentration and potentially a worsening of adverse effects.
 27 
The risk or severity of hypotension can be increased when drug2 is combined with drug1.
 25 
The risk or severity of hypotension can be increased when drug1 is combined with drug2.
 25 
drug2 may decrease the cardiotoxic activities of drug1.
 20 
The absorption of drug1 can be decreased when combined with drug2.
 20 
drug1 may decrease the cardiotoxic activities of drug2.
 20 
The absorption of drug2 can be decreased when combined with drug1.
 20 
drug2 may increase the antiplatelet activities of drug1.
 19 
drug1 may increase the antiplatelet activities of drug2.
 19 
The risk or severity of tendinopathy can be increased when drug2 is combined with drug1.
 17 
The risk or severity of tendinopathy can be increased when drug1 is combined with drug2.
 17 
The risk or severity of hypocalcemia can be increased when drug1 is combined with drug2.
 16 
The risk or severity of hypocalcemia can be increased when drug2 is combined with drug1.
 16 
drug2 may decrease the antihypertensive activities of drug1.
 15 
drug1 may decrease the antihypertensive activities of drug2.
 15 
drug1 may increase the vasoconstricting activities of drug2.
 12 
drug2 may increase the vasoconstricting activities of drug1.
 12 
The risk or severity of edema formation can be increased when drug1 is combined with drug2.
 11 
The risk or severity of edema formation can be increased when drug2 is combined with drug1.
 11 
The risk or severity of gastrointestinal bleeding can be increased when drug1 is combined with drug2.
 10 
The risk or severity of gastrointestinal bleeding can be increased when drug2 is combined with drug1.
 10 
The risk or severity of pulmonary toxicity can be increased when drug1 is combined with drug2.
 9 
The risk or severity of pulmonary toxicity can be increased when drug2 is combined with drug1.
 9 
The risk or severity of electrolyte imbalance can be increased when drug2 is combined with drug1.
 9 
The risk or severity of electrolyte imbalance can be increased when drug1 is combined with drug2.
 9 
The risk or severity of congestive heart failure can be increased when drug1 is combined with drug2.
 8 
The risk of a hypersensitivity reaction to drug2 is increased when it is combined with drug1.
 8 
drug1 may increase the sedative activities of drug2.
 8 
The risk or severity of respiratory depression can be increased when drug2 is combined with drug1.
 8 
drug2 may increase the sedative activities of drug1.
 8 
The risk of a hypersensitivity reaction to drug1 is increased when it is combined with drug2.
 8 
The risk or severity of congestive heart failure can be increased when drug2 is combined with drug1.
 8 
The risk or severity of respiratory depression can be increased when drug1 is combined with drug2.
 8 
drug1 may increase the QTc-prolonging activities of drug2.
 7 
drug2 may increase the QTc-prolonging activities of drug1.
 7 
drug1 may increase the hepatotoxic activities of drug2.
 6 
drug2 may increase the hepatotoxic activities of drug1.
 6 
The risk or severity of anemia can be increased when drug1 is combined with drug2.
 4 
The risk or severity of orthostatic hypotension and syncope can be increased when drug1 is combined with drug2.
 4 
The risk or severity of hypotension and orthostatic hypotension can be increased when drug1 is combined with drug2.
 4 
The risk or severity of sedation, somnolence, and CNS depression can be increased when drug2 is combined with drug1.
 4 
The risk or severity of sedation can be increased when drug2 is combined with drug1.
 4 
The risk or severity of sedation, somnolence, and CNS depression can be increased when drug1 is combined with drug2.
 4 
drug2 may increase the hypokalemic activities of drug1.
 4 
The risk or severity of orthostatic hypotension and syncope can be increased when drug2 is combined with drug1.
 4 
The risk or severity of sedation can be increased when drug1 is combined with drug2.
 4 
The risk or severity of fluid retention can be increased when drug2 is combined with drug1.
 4 
The risk or severity of anemia can be increased when drug2 is combined with drug1.
 4 
The risk or severity of hypotension and orthostatic hypotension can be increased when drug2 is combined with drug1.
 4 
drug1 may increase the hypokalemic activities of drug2.
 4 
The risk or severity of fluid retention can be increased when drug1 is combined with drug2.
 4 
The risk or severity of liver damage can be increased when drug1 is combined with drug2.
 3 
The risk or severity of increased transaminases can be increased when drug2 is combined with drug1.
 3 
The risk or severity of bradycardia can be increased when drug2 is combined with drug1.
 3 
The risk or severity of liver damage can be increased when drug2 is combined with drug1.
 3 
The risk or severity of increased transaminases can be increased when drug1 is combined with drug2.
 3 
The risk or severity of bradycardia can be increased when drug1 is combined with drug2.
 3 
The risk or severity of thromboembolism can be increased when drug2 is combined with drug1.
 2 
The risk or severity of adverse effects can be decreased when drug2 is combined with drug1.
 2 
The risk or severity of sedation and CNS depression can be increased when drug2 is combined with drug1.
 2 
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when drug1 is combined with drug2.
 2 
drug1 may increase the hypertensive activities of drug2.
 2 
The risk or severity of bleeding and thrombocytopenia can be increased when drug1 is combined with drug2.
 2 
drug2 may increase the hypertensive activities of drug1.
 2 
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when drug2 is combined with drug1.
 2 
The risk or severity of QTc prolongation and torsade de pointes can be increased when drug2 is combined with drug1.
 2 
The risk or severity of sedation and CNS depression can be increased when drug1 is combined with drug2.
 2 
The risk or severity of thromboembolism can be increased when drug1 is combined with drug2.
 2 
The risk or severity of adverse effects can be decreased when drug1 is combined with drug2.
 2 
The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when drug1 is combined with drug2.
 2 
The risk or severity of QTc prolongation and torsade de pointes can be increased when drug1 is combined with drug2.
 2 
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when drug2 is combined with drug1.
 2 
The risk or severity of bleeding and thrombocytopenia can be increased when drug2 is combined with drug1.
 2 
The serum concentration of dextroamphetamine, an active metabolite of drug2, can be increased when used in combination with drug1.
 1 
The risk or severity of confusion, irritability, and sleep disorders can be increased when drug1 is combined with drug2.
 1 
drug1 may increase the cardiotoxic activities of drug2.
 1 
drug1 may increase the nephrotoxic activities of drug2.
 1 
The risk or severity of neuromuscular blockade can be increased when drug2 is combined with drug1.
 1 
drug2 may increase the uterotonic activities of drug1.
 1 
drug1 may increase the uterotonic activities of drug2.
 1 
drug2 may increase the nephrotoxic activities of drug1.
 1 
The risk or severity of leukopenia can be increased when drug2 is combined with drug1.
 1 
drug2 may increase the cardiotoxic activities of drug1.
 1 
The risk or severity of neuromuscular blockade can be increased when drug1 is combined with drug2.
 1 
The serum concentration of dextroamphetamine, an active metabolite of drug1, can be increased when used in combination with drug2.
 1 
The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when drug1 is combined with drug2.
 1 
The risk or severity of ulceration can be increased when drug1 is combined with drug2.
 1 
The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when drug2 is combined with drug1.
 1 
The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when drug1 is combined with drug2.
 1 
The risk or severity of ventricular arrhythmias, bradycardia, and heart block can be increased when drug2 is combined with drug1.
 1 
The risk or severity of leukopenia can be increased when drug1 is combined with drug2.
 1 
The risk or severity of confusion, irritability, and sleep disorders can be increased when drug2 is combined with drug1.
 1 
The risk or severity of ulceration can be increased when drug2 is combined with drug1.
 1 
 
Number of unique sentences: 192